DE69735939T2 - Fhit proteine und nukleinsäuren sowie darauf basierende verfahren - Google Patents

Fhit proteine und nukleinsäuren sowie darauf basierende verfahren Download PDF

Info

Publication number
DE69735939T2
DE69735939T2 DE69735939T DE69735939T DE69735939T2 DE 69735939 T2 DE69735939 T2 DE 69735939T2 DE 69735939 T DE69735939 T DE 69735939T DE 69735939 T DE69735939 T DE 69735939T DE 69735939 T2 DE69735939 T2 DE 69735939T2
Authority
DE
Germany
Prior art keywords
fhit
protein
sequence
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735939T
Other languages
German (de)
English (en)
Other versions
DE69735939D1 (de
Inventor
M. Carlo Philadelphia CROCE
K. Frances Philadelphia HUEBNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/598,873 external-priority patent/US5928884A/en
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of DE69735939D1 publication Critical patent/DE69735939D1/de
Publication of DE69735939T2 publication Critical patent/DE69735939T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE69735939T 1996-02-09 1997-02-07 Fhit proteine und nukleinsäuren sowie darauf basierende verfahren Expired - Lifetime DE69735939T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US598873 1996-02-09
US08/598,873 US5928884A (en) 1996-02-09 1996-02-09 FHIT proteins and nucleic acids and methods based thereon
US605430 1996-02-22
US08/605,430 US6242212B1 (en) 1996-02-09 1996-02-22 Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins
PCT/US1997/001937 WO1997029119A1 (en) 1996-02-09 1997-02-07 Fhit proteins and nucleic acids and methods based thereon

Publications (2)

Publication Number Publication Date
DE69735939D1 DE69735939D1 (de) 2006-06-29
DE69735939T2 true DE69735939T2 (de) 2007-01-25

Family

ID=27083164

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735939T Expired - Lifetime DE69735939T2 (de) 1996-02-09 1997-02-07 Fhit proteine und nukleinsäuren sowie darauf basierende verfahren

Country Status (7)

Country Link
US (5) US6242212B1 (enExample)
EP (2) EP0892809B1 (enExample)
JP (1) JP2000502570A (enExample)
AT (1) ATE327326T1 (enExample)
AU (1) AU2262197A (enExample)
DE (1) DE69735939T2 (enExample)
WO (1) WO1997029119A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2406366A1 (en) * 2000-04-11 2001-10-18 Thomas Jefferson University Muir-torre-like syndrome infhit deficient mice
WO2002064172A2 (en) * 2001-02-12 2002-08-22 Thomas Jefferson University Fhit gene therapy prevents tumor development in fhit-deficient mice
WO2002064171A1 (en) * 2001-02-12 2002-08-22 Thomas Jefferson University Adenoviral transduction of fragile histidine triad (fhit) into cancer cells
WO2004082458A2 (en) 2003-02-21 2004-09-30 The Johns Hopkins University Tyrosine kinome
AU2004257362A1 (en) * 2003-07-15 2005-01-27 National Research Council Of Canada Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells
US7433520B1 (en) 2004-12-01 2008-10-07 Kilimanjaro Partnership Nosologic system of diagnosis
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
JP2009507918A (ja) * 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
JP2009532020A (ja) * 2006-03-03 2009-09-10 セ・イ・エ・エメ・ア・テ 紫外線に過敏な移植されたヒト皮膚を含むマウスモデル
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
WO2008091284A2 (en) * 2006-07-12 2008-07-31 Vanderbilt University Vectors for inducing homozygous mutations and methods of using same
EP2041317A4 (en) 2006-07-13 2009-10-14 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
EP2061907B1 (en) * 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
WO2008094545A2 (en) * 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
AU2008248319B2 (en) * 2007-04-30 2013-09-05 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
ES2537349T3 (es) * 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
US20090023138A1 (en) * 2007-07-17 2009-01-22 Zila Biotechnology, Inc. Oral cancer markers and their detection
CN101809169B (zh) * 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2653561B1 (en) * 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) * 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2775001B1 (en) * 2007-09-06 2016-03-09 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
EP2212440A4 (en) * 2007-10-11 2011-04-06 Univ Ohio State Res Found METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF ADENOCARCINOMES OF DISHES
CA2703707A1 (en) * 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
CN101918594A (zh) * 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
CN102027129B (zh) * 2008-02-28 2014-03-12 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
CA2717026A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
EP2307028B1 (en) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654419A (en) * 1984-08-08 1987-03-31 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen
US5362623A (en) * 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US5352775A (en) * 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
CA2060267A1 (en) * 1991-02-22 1992-08-23 Joe W. Gray Chromosome specific staining to detect genetic rearrangements
US5330892A (en) * 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
US6242212B1 (en) 2001-06-05
EP0892809A4 (en) 2002-10-09
EP0892809B1 (en) 2006-05-24
US20040265316A1 (en) 2004-12-30
US20050074797A1 (en) 2005-04-07
US20070178105A1 (en) 2007-08-02
JP2000502570A (ja) 2000-03-07
AU2262197A (en) 1997-08-28
EP1795203A3 (en) 2007-07-04
WO1997029119A1 (en) 1997-08-14
DE69735939D1 (de) 2006-06-29
US6774217B1 (en) 2004-08-10
EP1795203A2 (en) 2007-06-13
US7220834B2 (en) 2007-05-22
EP0892809A1 (en) 1999-01-27
ATE327326T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
DE69735939T2 (de) Fhit proteine und nukleinsäuren sowie darauf basierende verfahren
US5928884A (en) FHIT proteins and nucleic acids and methods based thereon
DE69836131T3 (de) Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
US9566294B2 (en) Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
DE69331832T3 (de) Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren
DE69631540T2 (de) Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs-suszeptilitaetsgens brca2 und dessen anwendungen
DE69738370T2 (de) Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
US6359193B1 (en) Nucleotide sequences of lats genes
DE69636365T2 (de) Peptide und zusammensetzungen, die die apoptose modulieren.
DE60034450T2 (de) 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase
US20060188924A1 (en) TCL-1 gene and protein and related methods and compositions
DE69535634T2 (de) Modulatoren der funktion des fas/ap01 rezeptors
DE10294485T5 (de) Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind
DE60128830T2 (de) Regulierung der expression von eer-7, ein mitglied der lysyl oxidase genfamilie, durch oestrogenrezeptoren
US6863887B1 (en) Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
DE69929958T2 (de) Modulatoren der funktion von rezeptoren der tnf/ngf rezeptorenfamilie
DE69806107T2 (de) Methoden und reagenzien zur regulierung von apoptosis
US5955579A (en) Islet-specific homeoprotein and transcriptional regulator of insulin gene expression, HOXB13
US5874290A (en) Nucleotide and amino acid sequences of a D2-2 gene associated with brain tumors and methods based thereon
US5990294A (en) Nucleotide and amino acid sequences of C4-2, a tumor suppressor gene, and methods of use thereof
CA2245783A1 (en) Fhit proteins and nucleic acids and methods based thereon
DE69839150T2 (de) Intrazelluläre glukocortikoid-induzierte leucin-zipper modulatoren von mechanismen des apoptotischen zelltodes
DE10008330A1 (de) Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren der Genfamilie NM23 zur Diagnose oder Behandlung von Haut- und Darmerkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition